Gene · 4070
Papers3,230
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
381 to 400 of 3,230
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Antibody-drug Conjugate Biomarker Expression in Gestational Trophoblastic Disease: Folate Receptor Alpha, Nectin-4, Trop-2, and Tissue Factor. | Int J Gynecol Pathol | 2026 | 40644332 | PubTator, text mining | PubMed |
| [Current and future treatment stratification of metastatic urothelial carcinoma: a great opportunity for true precision oncology]. | Aktuelle Urol | 2026 | 40592479 | PubTator, text mining | PubMed |
| Exploring the Therapeutic Potential of TROP2 Gene Silencing in Hepatocellular Carcinoma. | Recent Pat Biotechnol | 2026 | 39835546 | PubTator, text mining | PubMed |
| Development and preclinical evaluation of a novel FGFR3-targeted antibody-drug conjugate in bladder cancer. | Asian J Pharm Sci | 2025 | 41809890 | PubTator, text mining | PubMed |
| Mechanisms and Therapeutic Strategies to Overcome Immune Checkpoint Inhibitor Resistance in Melanoma, Head and Neck, and Triple-Negative Breast Cancers. | J Cell Immunol | 2025 | 41799379 | PubTator, text mining | PubMed |
| Associations between carotid artery intima-media thickness, traditional risk factors and proteins. | NPJ Cardiovasc Health | 2025 | 41775896 | PubTator, text mining | PubMed |
TROPION-Lung10: a phase 3 study of datopotamab deruxtecan and rilvegostomig in patients with treatment-naïve locally advanced or metastatic nonsquamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterations. | Front Oncol | 2025 | 41669261 | PubTator, text mining | PubMed |
| TROPHIT1-a randomized, open-label, multicenter, phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic colorectal cancer patients. | ESMO Gastrointest Oncol | 2025 | 41646480 | PubTator, text mining | PubMed |
| Antibody-Mediated Therapy in Gastric Cancer: Past, Present, and Future. | Curr Issues Mol Biol | 2025 | 41614808 | PubTator, text mining | PubMed |
| Sacituzumab govitecan as a therapeutic breakthrough in the treatment of triple-negative breast cancer: a systematic review of clinical trials. | Front Immunol | 2025 | 41601628 | PubTator, text mining | PubMed |
| TROP-2 expression in triple-negative and human epidermal growth factor receptor 2 enriched breast cancers and its relationship with clinicopathologic parameters. | Pol J Pathol | 2025 | 41549930 | PubTator, text mining | PubMed |
| Evaluation of the diagnostic utility of galectin-1 and TROP-2 in thyroid tumors: A retrospective analysis. | Qatar Med J | 2025 | 41480246 | PubTator, text mining | PubMed |
| Exploring EGFR, Nectin-4, and TROP-2 as Therapeutic Targets for Bladder Cancer Photoimmunotherapy. | Molecules | 2025 | 41471825 | PubTator, text mining | PubMed |
| Trop2 immuno-PET/CT imaging of prostate cancer: a proof-of-concept translational study. | BMC Med | 2025 | 41469668 | PubTator, text mining | PubMed |
TROPION-Lung15: a randomized phase III study of osimertinib combined with datopotamab deruxtecan (Dato-DXd) or Dato-DXd alone versus platinum-doublet chemotherapy in patients with EGFR-mutated advanced non-small cell lung cancer and whose disease has progressed on prior osimertinib. | Ther Adv Med Oncol | 2025 | 41466843 | PubTator, text mining | PubMed |
| Cost-effectiveness of antibody-drug conjugates in previously treated metastatic triple-negative breast cancer in China. | Health Econ Rev | 2025 | 41466127 | PubTator, text mining | PubMed |
| The efficacy and safety of datopotamab deruxtecan (Dato-DXd) in advanced solid tumors: a systematic review and meta-analysis. | Eur J Med Res | 2025 | 41462360 | PubTator, text mining | PubMed |
| Single-cell and spatial transcriptomics reveal the interaction between PRRX2-driven epithelial cells and SPP1+ macrophages in mediating gemcitabine resistance in pancreatic ductal adenocarcinoma. | Chin Med J (Engl) | 2025 | 41456929 | PubTator, text mining | PubMed |
| Expression of antibody-drug conjugate targets in post-mortem samples of breast cancer metastases and normal tissue. | Nat Commun | 2025 | 41449182 | PubTator, text mining | PubMed |
| [Up-to-Date Chemotherapy for Endometrial Cancer]. | Gan To Kagaku Ryoho | 2025 | 41437602 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4070/papers?page=20